Table 2.
Summary of ongoing trials (all in the recruiting phase) for the identification of predictive biomarkers for prostate cancer.
| Trial ID | Trial Description | Study Type | Conditions | Interventions | Outcomes Measures | Estimated Primary Completion Date |
|---|---|---|---|---|---|---|
| NCT04324983 | BioPoP, Identification of Predictive Biomarkers | Interventional | Prostate Cancer Recurrent |
Blood sample | -Rate of complete biochemical response -Prostate cancer-specific treatment-free survival after salvage surgery -Questionnaire Quality of life |
December 2021 |
| NCT03902951 | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | Interventional, Phase II | -Metastatic Prostate Adenocarcinoma -Recurrent Prostate Carcinoma |
-Drugs: Abiraterone Acetate/Apalutamide/Leuprolide Acetate -Stereotactic Body Radiation Therapy |
-Percent of patients achieving a PSA < 0.05 ng/mL -Time to biochemical/ radiographic progression -Time to initiation of alternative antineoplastic therapy -Prostate cancer-specific Survival -Health-related quality of life -Biomarker analysis |
July 2021 |
| NCT03421015 | Genetic Analysis of Prostate Cancer to Identify PredictiveMarkers of Disease Relapse or Metastatic Evolution | Observational Retrospective | Prostate Cancer | - | -The genetic alteration frequencies of TMPRSS2- ERG gene fusion •Frequency of amplification of proto-oncogenes (MYC, AR, PIK3CA) •Frequency of mutations or deletions of tumor suppressor genes (PTEN, TP53, NKX3-1), •Frequency of point mutations modifying protein function |
July 2020 |